jsharpe

About Jenny Sharpe

This author has not yet filled in any details.
So far Jenny Sharpe has created 273 blog entries.

Globally Applicable Facilitated Regulatory Pathways to Improve Equitable Access to Medicines

A variety of approaches have been developed to accelerate the regulatory review of medicines. We characterise these various expedited pathways as facilitated regulatory pathways (FRPs): regulatory pathways designed to accelerate [...]

2026-02-05T16:45:35+00:00July 19th, 2017|Tags: , |

CIRS RD Briefing 62 – New drug approvals in ICH countries 2007-2016

There have been major improvements in the regulatory environment in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) countries over the [...]

2026-02-05T16:46:25+00:00April 1st, 2017|Tags: |

CIRS RD Briefing 61: Building quality into decision-making processes

In 2015, CIRS initiated a programme in Quality Decision Making with the following aims: Evaluate the current decision-frameworks and understand the characteristics of different decision-making processes Assess the quality [...]

2026-02-05T16:47:05+00:00January 1st, 2017|Tags: |

Haqaish et al 2017 – Jordan Food and Drug Administration: Comparison of its Registration Process with Australia, Canada, Saudi Arabia and Singapore

Objective: This study compares the current regulatory review process and good review practices at the Saudi Food and Drug Authority (SFDA) with those of regulatory agencies in Australia, Canada, [...]

2026-02-05T16:44:11+00:00January 1st, 2017|Tags: , |

Bujar et al 2016 – Quality of Regulatory Decision-Making Practices

Background The science of decision making is well established, although in reality it is a mixture of science and art. What is currently lacking is research into decision making [...]

2026-02-20T14:57:06+00:00December 30th, 2016|Tags: , |

CIRS RD Briefing 59 – New approvals in six regulatory authorities 2006-2015

The last decade, 2006-2015, has seen a continuation of the convergence and general decrease in the approval times amongst six major regulatory authorities, namely the European Medicines Agency (EMA), [...]

2026-02-05T16:49:30+00:00May 16th, 2016|Tags: |
Go to Top